Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Pleomorphic T-cell lymphoma
Pleomorphic T-cell lymphoma (also known as "Non-mycosis fungoides CD30− pleomorphic small/medium sized cutaneous T-cell lymphoma") is a cutaneous condition characterized by a 5-year survival rate of 62%.